既往SARS-CoV-2感染者长期抗体持久性与优异疫苗应答
研究比较既往感染COVID-19的卫生专业人员与未感染者的抗体应答,发现既往感染者首剂后21天抗体水平约为未感染者第二剂后21天的10倍,血清阳性持续至少11个月。作者建议疫苗短缺时既往感染者可暂缓接种,供应正常后考虑单剂接种。
要点
- 既往感染者首剂后21天抗体水平约为未感染者两剂后21天的10倍。
- 血清阳性至少持续11个月。
- 疫苗短缺时既往感染者可暂缓接种,供应正常后考虑单剂。
核心结论
- 疫苗短缺期间,既往SARS-CoV-2感染者应从接种活动中暂缓。
- 当剂量供应恢复正常时,应考虑对血清阳性个体仅注射单剂。
研究设计与样本
- 研究对象为从COVID-19康复或从未感染SARS-CoV-2的卫生专业人员。
- 在接种前及接种后多个时间点进行血清学检测。
主要发现
- 既往感染者首剂后21天抗体应答约为未感染者第二剂后21天的10倍。
- 血清阳性持续至少11个月。
临床怎么用
- 疫苗短缺时可优先将剂量分配给血清阴性者,既往感染者暂缓。
- 供应正常后对血清阳性个体可考虑单剂接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The first COVID-19 vaccines are being distributed to the general population. However, the shortage of doses is slowing down the goal of reaching herd immunity. The aim of the study was to verify whether previously SARS-CoV-2 infected subjects, a considerable portion of the population, should receive the same vaccination treatment of seronegative individuals. METHODS: Health-professionals either recovered from COVID-19 or never infected by SARS-CoV-2 were serologically tested at different time-points right before, and several days after, vaccination. RESULTS: Previously infected individuals showed humoral immune responses, 21 days after the first dose, that was approximately 10-folds higher than the seronegative group 21 days after the second dose. Seropositivity persists for at least 11 months. CONCLUSION: During a shortage of COVID-19 vaccine doses, previously SARS-CoV-2 infected individuals should be dispensed from the vaccination campaign. When dose availability returns to normality, injection of a single dose for seropositive individuals should be considered.
引用
- Ferrari D, Di Resta C, Tomaiuolo R, et al. Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects. Vaccine. 2021. PMID: 34147292. doi:10.1016/j.vaccine.2021.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。